Awareness : Newsletter Articles

Ranibizumab (Lucentis®) – Revision to Part A and Part B LCD”

The revision related to the addition of myopic choroidal neovascularization is effective for claims processed on or after June 1, 2017, for services rendered on or after January 5, 2017. The revision related to the addition of diabetic retinopathy is effective for claims processed on or after June 1, 2017

In addition, ICD-10- CM diagnosis codes were added to support medical necessity section of HCPCS code J2778:


  • E10.319, E10.3291-E10.3293,
  • E10.3391-E10.3393, E10.3491-E10.3493,
  • E10.3591-E10.3593, E11.319, E11.3291-E11.3293,
  • E11.3391-E11.3393, E11.3491-E11.3493,
  • E11.3591-E11.3593, E13.319, E13.3291-E13.3293,
  • E13.3391-E13.3393, E13.3491-E13.3493,
  • E13.3591-E13.3593, and H35.051-H35.053